Your browser doesn't support javascript.
Severe COVID-19 pneumonia in Piacenza, Italy - A cohort study of the first pandemic wave.
Guglielmetti, Lorenzo; Kontsevaya, Irina; Leoni, Maria C; Ferrante, Patrizia; Fronti, Elisa; Gerna, Laura; Valdatta, Caterina; Donisi, Alessandra; Faggi, Alberto; Paolillo, Franco; Ratti, Giovanna; Ruggieri, Alessandro; Scotti, Marta; Sacchini, Daria; Taliani, Gloria; Codeluppi, Mauro.
  • Guglielmetti L; Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France; APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux
  • Kontsevaya I; Research Center Borstel, Borstel, Germany; German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany. Electronic address: ikontsevaya@fz-borstel.de.
  • Leoni MC; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: M.Leoni2@ausl.pc.it.
  • Ferrante P; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy; Institute for Cross-Disciplinary Physics and Complex Systems IFISC (UIB-CSIC), Campus Universitat Illes Balears, E-07122 Palma de Mallorca, Spain. Electronic address: P.Ferrante@ausl.pc.it.
  • Fronti E; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: E.Fronti@ausl.pc.it.
  • Gerna L; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: L.Gerna@ausl.pc.it.
  • Valdatta C; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: C.Valdatta@ausl.pc.it.
  • Donisi A; Migration Health Unit, Primary Health Care Department, "Guglielmo da Saliceto" Hospital, Piacenza, Italy. Electronic address: a.donisi@ausl.pc.it.
  • Faggi A; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: A.Faggi@ausl.pc.it.
  • Paolillo F; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: F.Paolillo@ausl.pc.it.
  • Ratti G; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: G.Ratti@ausl.pc.it.
  • Ruggieri A; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: A.Ruggieri@ausl.pc.it.
  • Scotti M; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: M.Scotti@ausl.pc.it.
  • Sacchini D; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: D.Sacchini@ausl.pc.it.
  • Taliani G; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy; Infectious and Tropical Disease Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Anti-COVID Task Force of the Italian Civil Protection. Electronic address: gloria.taliani@uniroma1.it.
  • Codeluppi M; Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy. Electronic address: m.codeluppi@ausl.pc.it.
J Infect Public Health ; 14(2): 263-270, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-966884
ABSTRACT

BACKGROUND:

Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and has the highest national COVID-19 death rates per population. The objective of this study is to present characteristics and outcomes of patients admitted to medical departments of the Hospital of Piacenza during the first wave of the epidemic.

METHODS:

A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards model was fit to assess the association of treatment and other variables with death.

RESULTS:

Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome (ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 (50%) patients. Most patients received antiviral treatment (187, 86%) and corticosteroids (134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at admission were associated with mortality, while having diarrhea at admission was associated with survival. The use of antivirals or corticosteroids was not associated with survival.

CONCLUSIONS:

Overall case fatality rates were high and associated with comorbidities, extensive lung involvement, ARDS at admission, and advanced age. The use of antivirals was not associated with increased survival.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2021 Document Type: Article